Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) had its target price lifted by JPMorgan Chase & Co. from $330.00 to $338.00 in a report released on Thursday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company's stock.

Other analysts have also recently issued research reports about the stock. Chardan Capital boosted their price target on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Citigroup increased their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. HC Wainwright restated a "buy" rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Finally, Redburn Atlantic started coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $319.58.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded up $6.09 during trading on Thursday, reaching $304.67. The company's stock had a trading volume of 874,326 shares, compared to its average volume of 931,682. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company's fifty day moving average is $268.41 and its 200-day moving average is $258.64. The company has a market capitalization of $39.73 billion, a P/E ratio of -140.40 and a beta of 0.22. Alnylam Pharmaceuticals has a 1 year low of $152.30 and a 1 year high of $310.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period in the prior year, the company earned ($0.16) EPS. The company's quarterly revenue was up 20.2% compared to the same quarter last year. On average, research analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the transaction, the chief executive officer now directly owns 48,948 shares in the company, valued at $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ALNY. Capital World Investors boosted its position in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after purchasing an additional 92,101 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after buying an additional 323,206 shares in the last quarter. Capital Research Global Investors boosted its holdings in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. increased its holdings in Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after buying an additional 33,696 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.